RECOMMENDATIONS AND GUIDELINES
ISTH DIC subcommittee communication on anticoagulation in COVID‐19

https://doi.org/10.1111/jth.15004Get rights and content
Under an Elsevier user license
open archive

Abstract

Hypercoagulability is an increasingly recognized complication of SARS‐CoV‐2 infection. As such, anticoagulation has become part and parcel of comprehensive COVID‐19 management. However, several uncertainties exist in this area, including the appropriate type and dose of heparin. In addition, special patient populations, including those with high body mass index and renal impairment, require special consideration. Although the current evidence is still insufficient, we provide a pragmatic approach to anticoagulation in COVID‐19, but stress the need for further trials in this area.

Keywords

anticoagulant
coagulopathy
Covid‐19
D‐dimer
prothrombin time

Cited by (0)

Manuscript handled by: Marc Carrier

Final decision: Marc Carrier, 09‐Jul‐2020